Related references
Note: Only part of the references are listed.Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study
Ola Olen et al.
LANCET (2020)
Colorectal cancer in Crohn's disease: a Scandinavian population-based cohort study
Ola Olen et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)
Zolbetuximab combined with EOX as first-line therapy in advanced CLDN18.2+gastric (G) and gastroesophageal junction (GEJ) adenocarcinoma: Updated results from the FAST trial.
Ugur Sahin et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
Funda Meric-Bemstam et al.
LANCET ONCOLOGY (2019)
Colitis-associated colorectal adenocarcinomas are frequently associated with non-intestinal mucin profiles and loss of SATB2 expression
Mai Iwaya et al.
MODERN PATHOLOGY (2019)
Detection of ERBB2 Amplification by Next-Generation Sequencing Predicts HER2 Expression in Colorectal Carcinoma
Odise Cenaj et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2019)
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study
O. Tuereci et al.
ANNALS OF ONCOLOGY (2019)
Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases
Irene Coati et al.
BRITISH JOURNAL OF CANCER (2019)
Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer
Funda Meric-Bernstam et al.
CLINICAL CANCER RESEARCH (2019)
Clinical Implications of Claudin18.2 Expression in Patients With Gastric Cancer
Jin Ho Baek et al.
ANTICANCER RESEARCH (2019)
Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma
Christoph Rohde et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2019)
Alterations in the epithelial stem cell compartment could contribute to permanent changes in the mucosa of patients with ulcerative colitis
Isabella Dotti et al.
GUT (2017)
HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology
Angela N. Bartley et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Reflux esophagitis and its role in the pathogenesis of Barrett's metaplasia
Rhonda Frances Souza
JOURNAL OF GASTROENTEROLOGY (2017)
SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type
Michelle Moh et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2016)
Genomic Alterations Observed in Colitis-Associated Cancers Are Distinct From Those Found in Sporadic Colorectal Cancers and Vary by Type of Inflammatory Bowel Disease
Rona Yaeger et al.
GASTROENTEROLOGY (2016)
Whole-Exome Sequencing Analyses of Inflammatory Bowel Disease-Associated Colorectal Cancers
Ana I. Robles et al.
GASTROENTEROLOGY (2016)
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Andrea Sartore-Bianchi et al.
LANCET ONCOLOGY (2016)
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
Emanuele Valtorta et al.
MODERN PATHOLOGY (2015)
Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis
C. Castano-Milla et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Cadherin-17 and SATB2 Are Sensitive and Specific Immunomarkers for Medullary Carcinoma of the Large Intestine
Fan Lin et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2014)
Declining Risk of Colorectal Cancer in Inflammatory Bowel Disease: An Updated Meta-analysis of Population-based Cohort Studies
Maurice W. M. D. Lutgens et al.
INFLAMMATORY BOWEL DISEASES (2013)
Expression profiling of claudins in the human gastrointestinal tract in health and during inflammatory bowel disease
Anke L. Lameris et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2013)
Claudins of intestine and nephron - a correlation of molecular tight junction structure and barrier function
S. Amasheh et al.
ACTA PHYSIOLOGICA (2011)
A Comparison of Equivocal Immunohistochemical Results With Anti-HER2/neu Antibodies A0485 and SP3 With Corresponding FISH Results in Routine Clinical Practice
Elizabeth Manion et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2011)
SATB2 in Combination With Cytokeratin 20 Identifies Over 95% of all Colorectal Carcinomas
Kristina Magnusson et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2011)
Predicted expansion of the claudin multigene family
Katsuhiko Mineta et al.
FEBS LETTERS (2011)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Immunohistochemical analysis of colorectal cancer with gastric phenotype: Claudin-18 is associated with poor prognosis
Miho Matsuda et al.
PATHOLOGY INTERNATIONAL (2010)
Immunohistochemical staining of Reg IV and claudin-18 is useful in the diagnosis of gastrointestinal signet ring cell carcinoma
Kazuhiro Sentani et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2008)
Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development
Ugur Sahin et al.
CLINICAL CANCER RESEARCH (2008)
Increased Expression of the Tight Junction Molecule Claudin-18 A1 in Both Experimental Colitis and Ulcerative Colitis
Antonie Zwiers et al.
INFLAMMATORY BOWEL DISEASES (2008)
claudin-18, a novel downstream target gene for the T/EBP/NKX2.1 homeodomain transcription factor, encodes lung- and stomach-specific isoforms through alternative splicing
T Niimi et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Multifunctional strands in tight junctions
S Tsukita et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
